[go: up one dir, main page]

WO1999013064A3 - Infection virale de cellules - Google Patents

Infection virale de cellules Download PDF

Info

Publication number
WO1999013064A3
WO1999013064A3 PCT/GB1998/002753 GB9802753W WO9913064A3 WO 1999013064 A3 WO1999013064 A3 WO 1999013064A3 GB 9802753 W GB9802753 W GB 9802753W WO 9913064 A3 WO9913064 A3 WO 9913064A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
viral
infecting
infected
viral vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB1998/002753
Other languages
English (en)
Other versions
WO1999013064A2 (fr
Inventor
Marc Feldmann
Brian Maurice John Foxwell
Fionula Mary Brennan
Jan Bondeson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kennedy Trust for Rheumatology Research
Original Assignee
Kennedy Institute of Rheumotology
Mathilda and Terence Kennedy Institute of Rheumatology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kennedy Institute of Rheumotology, Mathilda and Terence Kennedy Institute of Rheumatology filed Critical Kennedy Institute of Rheumotology
Priority to JP2000510853A priority Critical patent/JP2001515716A/ja
Priority to EP98942892A priority patent/EP1012321A2/fr
Publication of WO1999013064A2 publication Critical patent/WO1999013064A2/fr
Publication of WO1999013064A3 publication Critical patent/WO1999013064A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention porte sur un procédé in vitro visant à infecter une ou plusieurs cellules avec un vecteur viral capable de transporter l'acide nucléique exogène ou recombinant dans ces cellules. Ce procédé consiste à: a) recueillir les cellules devant être infectées; b) traiter les cellules infectées avec au moins une cytokine; et c) infecter les cellules recueillies avec un vecteur viral tel qu'un adénovirus. L'invention porte également sur un procédé visant à infecter des cellules synoviales rhumatoïdes et d'autres cellules comportant des taux élevés d'intégrines à leur surface.
PCT/GB1998/002753 1997-09-11 1998-09-11 Infection virale de cellules Ceased WO1999013064A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2000510853A JP2001515716A (ja) 1997-09-11 1998-09-11 細胞のウイルス感染
EP98942892A EP1012321A2 (fr) 1997-09-11 1998-09-11 Infection virale de cellules

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9719238.9 1997-09-11
GBGB9719238.9A GB9719238D0 (en) 1997-09-11 1997-09-11 Viral infection of cells

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09508350 A-371-Of-International 2000-04-07
US10/033,267 Continuation US20020177572A1 (en) 1997-09-11 2001-10-25 Viral infection of cells

Publications (2)

Publication Number Publication Date
WO1999013064A2 WO1999013064A2 (fr) 1999-03-18
WO1999013064A3 true WO1999013064A3 (fr) 1999-06-17

Family

ID=10818857

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1998/002753 Ceased WO1999013064A2 (fr) 1997-09-11 1998-09-11 Infection virale de cellules

Country Status (4)

Country Link
EP (1) EP1012321A2 (fr)
JP (1) JP2001515716A (fr)
GB (1) GB9719238D0 (fr)
WO (1) WO1999013064A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9922281D0 (en) * 1999-09-22 1999-11-17 Kennedy Rheumatology Inst Polymorphism
GB9930616D0 (en) 1999-12-24 2000-02-16 Mathilda & Terence Kennedy Ins Activation and inhibition of the immune system
US7105336B2 (en) * 2002-10-07 2006-09-12 Biogaia Ab Selection and use of lactic acid bacteria for reducing inflammation caused by Helicobacter

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0779361A2 (fr) * 1995-12-15 1997-06-18 F. Hoffmann-La Roche Ag Forme tronquée de la protéine inhibitrice kappa B, production récombinante et utilisation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0779361A2 (fr) * 1995-12-15 1997-06-18 F. Hoffmann-La Roche Ag Forme tronquée de la protéine inhibitrice kappa B, production récombinante et utilisation

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
B. FOXWELL ET AL.,: "Efficient adenoviral infection with IkappaB alpha reveals that macrophage tumor necrosis alpha production in rheumatoid arthritis is NF-kappaB dependent", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 95, no. 14, 1998, pages 8211 - 8215, XP002098099 *
BAEUERLE P A ET AL: "FUNCTION AND ACTIVATION OF NF-KappaB INTHE IMMUNE SYSTEM", ANNUAL REVIEW OF IMMUNOLOGY, vol. 12, 1994, pages 141 - 179, XP000612175 *
C. JOBIN ET AL.,: "Inhibition of proinflammatory molecule production by adenovirus-mediated expression of a nuclear factor kappa-beta super-repressor in human intestinal epithelial cells.", JOURNAL OF INMUNOLOGY, vol. 160, no. 1, 1 January 1998 (1998-01-01), pages 410 - 418, XP002098101 *
C. JOBIN ET AL.,: "Potential novel therapy for the intestine: adenoviral mediated gene delivery of an NF-kappa super-repressor blocked proinflammatory gene expression in human intestinal epithelial cells", GASTROENTEROLOGY, vol. 112, no. (4 suppl.), 1997, pages pA1006, XP002098097 *
HADDADA H ET AL: "EFFICIENT ADENOVIRUS-MEDIATED GENE TRANSFER INTO HUMAN BLOOD MONOCYTE-DERIVED MACROPHAGES", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 195, no. 3, 30 September 1993 (1993-09-30), pages 1174 - 1183, XP002005682 *
H-G ZHANG ET AL.,: "Increased susceptibility of RA synovial cells to TNFalpha-mediated apoptosis after IKB dominate negative gene therapy", ARTHRITIS AND RHEUMATISM, vol. 41, no. (9 suppl.), 1 September 1998 (1998-09-01), pages ps96, XP002098100 *
M. FELDMAN ET AL.,: "Anti-TNFalpha therapy is useful in rheumatoid arthritis and Crohn's disease: analysis of the mechanism of action predicts utility in other diseases", TRANSPLANTATION PROCEEDINGS, vol. 30, no. 8, 1 December 1998 (1998-12-01), pages 4126 - 4127, XP002098301 *
PAHL H L ET AL: "The ER-overload response: activation of NF-kappaB", TIBS TRENDS IN BIOCHEMICAL SCIENCES, vol. 22, no. 2, February 1997 (1997-02-01), pages 63-67, XP004050133 *
S. HUANG ET AL.,: "Upregulation of integrins alpha-v-beta-3 and alpha-v-beta-5 on human monocytes and T lymphocytes facilitates adenovirus-mediated gene delivery", JOURNAL OF VIROLOGY, vol. 69, no. 4, 1995, pages 2257 - 2263, XP002098096 *
S.S. MAKAROV ET AL.,: "NF-kappa B as a target for anti-inflammatory gene therapy: Suppression of inflammatory responses in monocytic and stromal cells by stable gene transfer of I-kappa-B-alpha cDNA", GENE THERAPY, vol. 4, no. 8, 1997, pages 846 - 852, XP002098098 *

Also Published As

Publication number Publication date
GB9719238D0 (en) 1997-11-12
JP2001515716A (ja) 2001-09-25
WO1999013064A2 (fr) 1999-03-18
EP1012321A2 (fr) 2000-06-28

Similar Documents

Publication Publication Date Title
WO2000008191A3 (fr) Virus d'herpes destines aux cellules dendritiques
EP0484374A4 (en) Rapid, versatile and simple system for expressing genes in eukaryotic cells
NO964445L (no) DNA-sekvens, vektor, vertscelle og fremgangsmåte for transfeksjon av hematopoeseceller med eksogen DNA
CA2092680A1 (fr) Sequences du virus epstein-barr et proteine comprise dans lesdites sequences
NZ500740A (en) Recombinant lentivirus-based gene transfer vectors comprising 3 vectors from Equine Infectious Anemia Virus (EIAV)
NZ320276A (en) Method and preparations for stabilizing biological materials by drying methods without freezing
GB2217718B (en) Recombinant viruses,vaccines containing them and in vitro cell cultures thereof
ZA979732B (en) Infectious clones of RNA viruses and vaccines and diagnostic assays derived therof.
CA2236968A1 (fr) Fonctions accessoires servant a produire des virions de vaa recombines
HU9502949D0 (en) Polipeptides, polinucleotides, vectors and host cells, and vaccines against hepatitis virus infection, diagnostics, immunoassay and culturing methods
EP1923467A3 (fr) Vecteurs d'adénovirus pour thérapie génétique
CA2020668A1 (fr) Proteines fusionnees ou hybrides comprenant de la lymphokine et un antigene viral
EP0702716A4 (fr) Therapie genique ribozymique contre l'infection par le vih et contre le sida
WO2000053729A3 (fr) Particules virales liberees apres infection par le virus cytomegalique humain et leur utilisation comme vaccin
AUPN477695A0 (en) Gene therapy
CA2437962A1 (fr) Methode d'extraction d'un virus a partir d'une culture cellulaire
WO2001055362A3 (fr) Vecteur adeno-retroviral hybride pour la transfection de cellules
CA2306449A1 (fr) Generation rapide de lignees cellulaires mammiferes stables produisant des niveaux eleves de proteines recombinantes
FR2606029B2 (fr) Vecteur viral et adn recombinant codant pour une glycoproteine du virus agent causal du s.i.d.a., culture cellulaire infectee par ce vecteur, procede de preparation de la glycoproteine, glycoproteine obtenue, vaccin et anticorps obtenus
WO1999013064A3 (fr) Infection virale de cellules
WO1999053047A3 (fr) Genome d'adenovirus porcin de type 3
AU5318496A (en) Adenovirus vectors for gene therapy
WO1994013812A3 (fr) Nouveaux genes de l'entomopoxvirus, nouvelles proteines et leurs procedes d'utilisation
ATE316139T1 (de) Attenuierte pferdeherpesvirus
EP0326127A3 (fr) Mutants d'insertion du virus de la rhinotrachéite infectieuse bovine, vaccins qui les contiennent et procédé pour leur préparation et applications

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 1998942892

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09508350

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1998942892

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1998942892

Country of ref document: EP